●] Shares FUSION PHARMACEUTICALS INC. COMMON SHARES UNDERWRITING AGREEMENTUnderwriting Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTSMFusion Pharmaceuticals Inc. • July 2nd, 2021 • Biological products, (no disgnostic substances) • New York
Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), common shares in the capital of the Company (the “Common Shares”), having an aggregate offering price of up to $100,000,000 on the terms set forth in this agreement (this “Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (“Parent Company”), Fusion Pharmaceuticals US, Inc., a Delaware corporation and US subsidiary of the Parent Company (the “Company”), and John Crowley (the “Executive”) and is effective as of the closing of the first underwritten public offering of the equity securities of the Parent Company pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Parent Company and/or the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Parent Company dated February 19, 2019 and revised February 22, 2019 (the “Prior Agreement”), and (ii) any offer letter, employment agreement or s
FUSION PHARMACEUTICALS INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Fusion Pharmaceuticals Inc. (the “Company”), a corporation existing under the Canada Business Corporations Act (the “CBCA”), and [Officer Name] (“Indemnitee”). 1
FUSION PHARMACEUTICALS INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Fusion Pharmaceuticals Inc. (the “Company”), a corporation existing under the Canada Business Corporations Act (the “CBCA”), and [Director Name] (“Indemnitee”).
ContractFusion Pharmaceuticals Inc. • March 16th, 2023 • Biological products, (no disgnostic substances) • New York
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 11th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 10, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 16th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (“Parent Company”), Fusion Pharmaceuticals US Inc., a Delaware corporation and US subsidiary of the Parent Company (the “Company”), and Dmitri Bobilev (the “Executive”) and is effective as of November 7, 2022, or such other date as may be agreed upon by the parties based on the timing of Executive’s separation from Executive’s current employer, and in any case conditional on such separation and on the Company’s determination that Executive is not restricted by any agreement between Executive and such employer from commencing employment with the Company (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 22nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and John Valliant (the “Executive”) and is effective as of the closing of the first underwritten public offering of the equity securities of the Company pursuant to an effective registration statement under the Securities Act of 1933, as amended (United States) (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the Employment Agreement between the Executive and the Company dated October 12, 2018 (the “Prior Agreement”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of the 19th day of December, 2016 (the “Effective Date”), by and between Fusion Pharmaceuticals Inc., a Canadian corporation with a place of business at 1280 Main Street West, NRB-A316, Hamilton, Ontario, Canada L8S 4Kl (“Licensee”) and ImmunoGen, Inc., a Massachusetts corporation with offices at 830 Winter Street, Waltham, MA 02451-1477, USA (“ImmunoGen”). Licensee and ImmunoGen may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 11th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of May 10, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of May 10, 2023 (the “Purchase Agreement”). Capitalized terms used herein shall have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
LEASE AGREEMENT Between McMASTER UNIVERSITY (the “Landlord”) –and– FUSION PHARMACEUTICALS INC., A body corporate incorporated under the laws of the Province of Ontario (the “Tenant”) Part of 270 Longwood Road South, HamiltonLease Agreement • June 3rd, 2021 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
WHEREAS The Gore District Land Trustee Corporation (“Gore”) is the registered owner of the lands upon which the McMaster Innovation Park (“MIP”) is situated within the City of Hamilton
Amendment. No. 2 to COLLABORATION AGREEMENTFusion Pharmaceuticals Inc. • November 9th, 2021 • Biological products, (no disgnostic substances)
This Amendment No. 2 , (this “Amendment”) dated as of July 27, 2021 (the “Effective Date”), to that certain Collaboration Agreement, dated as of December 10, 2020 and amended on June 28, 2021 (collectively, the “Agreement”), by and between, on the one hand, Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its registered offices at 270 Longwood Road S, Hamilton, Ontario L8P 0A6, Canada (“FPI”) and, on the other hand, TRIUMF Innovations Inc. (“TI”), a not-for-profit corporation continued under the Canada Not-for-profit Corporations Act, with its registered offices at 4004 Wesbrook Mall, Vancouver BC V6T 2A3, Canada and TRIUMF JV, a joint venture of The Governors of The University of Alberta, The University of British Columbia, The Governors of the University of Calgary, Carleton University, University of Guelph, University of Manitoba, McMaster University, Université de Montréal, Queen’s University, University of Regina, Simon Fraser University, The Governing Council of
EMPLOYMENT AGREEMENTEmployment Agreement • March 17th, 2022 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (“Parent Company”), Fusion Pharmaceuticals US, Inc., a Delaware corporation and US subsidiary of the Parent Company (the “Company”), and Mohit Rawat (the “Executive”) and is effective as of September 27, 2021 (the “Effective Date”).
OPTION AND ASSET PURCHASE AGREEMENT dated as of November 14, 2022 by and between RADIOMEDIX, INC. and FUSION PHARMACEUTICALS INC.Option and Asset Purchase Agreement • February 14th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Option and Asset Purchase Agreement (this “Agreement”), dated as of November 14, 2022, is entered into by and between Fusion Pharmaceuticals Inc., a Canadian federal corporation (“Buyer”), and RadioMedix, Inc., a Texas corporation (“Seller”). Seller and Buyer are sometimes referred to in this Agreement collectively as the “Parties” and individually as a “Party”.
ASSET PURCHASE AGREEMENT dated as of March 1, 2021 by and between IPSEN PHARMA SAS and FUSION PHARMACEUTICALS INC.Asset Purchase Agreement • March 2nd, 2021 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Asset Purchase Agreement (this “Agreement”), dated as of March 1, 2021, is entered into by and between Fusion Pharmaceuticals Inc., a Canadian federal corporation (“Buyer”), and Ipsen Pharma SAS, a French société par actions simplifiée (“Seller”). Seller and Buyer are sometimes referred to in this Agreement collectively as the “Parties” and individually as a “Party”.
AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 25th, 2021 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment No. 2 to Asset Purchase Agreement (this “Second Amendment”), effective as of February 8, 2021 (the “Second Amendment Effective Date”), is entered into by and among Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its principal place of business at 270 Longwood Road S., Hamilton, Ontario L8P 0A6 (“Purchaser”); Rainier Therapeutics, Inc., a Delaware corporation with its principal place of business at 500 Mercer Street, Suite C202, Seattle, Washington 98109 (“Seller”); and Fortis Advisors LLC, a Delaware limited liability company solely in its capacity as the representative for Seller for certain obligations (“Seller Representative”). Purchaser, Seller, and Seller Representative are referred to herein individually as a “Party” and collectively, as the “Parties”.
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 10th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment No. 1 to Asset Purchase Agreement (this “Amendment”), effective as of October 8, 2020 (the “Amendment Effective Date”), is entered into by and among Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its principal place of business at 270 Longwood Road S., Hamilton, Ontario L8P 0A6 (“Purchaser”); Rainier Therapeutics, Inc., a Delaware corporation with its principal place of business at 500 Mercer Street, Suite C202, Seattle, Washington 98109 (“Seller”); and Fortis Advisors LLC, a Delaware limited liability company solely in its capacity as the representative for Seller for certain obligations (“Seller Representative”). Purchaser, Seller, and Seller Representative are referred to herein individually as a “Party” and collectively, as the “Parties”.
COLLABORATION AGREEMENTCollaboration Agreement • November 9th, 2021 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
This Collaboration Agreement (this “Agreement”) is made as of December 10, 2020 (the “Effective Date”), by and between, on the one hand, Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its registered offices at 270 Longwood Road S, Hamilton, Ontario L8P 0A6, Canada (“FPI”) and, on the other hand, TRIUMF Innovations Inc. (“TI”), a not-for-profit corporation continued under the Canada Not-for-profit Corporations Act, with its registered offices at 4004 Wesbrook Mall, Vancouver BC V6T 2A3, Canada and TRIUMF JV, a joint venture of The Governors of The University of Alberta, The University of British Columbia, The Governors of the University of Calgary, Carleton University, University of Guelph, University of Manitoba, McMaster University, Université de Montréal, Queen’s University, University of Regina, Simon Fraser University, The Governing Council of the University of Toronto, The University of Victoria and York University, and such other universities who have become or
AMENDMENT No. 1 EMPLOYMENT AGREEMENTEmployment Agreement • March 25th, 2021 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (the “Amendment”) to that certain Employment Agreement, dated as of June 25, 2020 (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and Eric Burak (the “Executive”) and is effective as of February 19, 2021 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 20th, 2024 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and Eric Burak (the “Executive”) and is effective as of December 18, 2023 (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the Employment Agreement between the Executive and the Company dated February 16, 2017, and the Employment Agreement dated June 25, 2020 and amended on February 19, 2021 (the “Prior Agreements”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
This AGREEMENT dated as of February 22, 2017 is made by and between Fusion Pharmaceuticals Inc. a Canadian corporation, having its principal place of business at NRB-A316, 1280 Main St West, Hamilton, ON. L8S 4K1 (“Fusion”) and the Centre for Probe Development and Commercialization Inc., a Canadian corporation, having its principal place of business at NRB-A316, 1280 Main St West, Hamilton, ON L8S 4K1 (“CPDC”).
Amendment. No. 3 to COLLABORATION AGREEMENTFusion Pharmaceuticals Inc. • November 9th, 2021 • Biological products, (no disgnostic substances)
This Amendment No. 3 , (this “Amendment”) dated as of August 12, 2021 (the “Effective Date”), to that certain Collaboration Agreement, dated as of December 10, 2020 and amended on June 28, 2021 and July 27, 2021 (collectively, the “Agreement”), by and between, on the one hand, Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its registered offices at 270 Longwood Road S, Hamilton, Ontario L8P 0A6, Canada (“FPI”) and, on the other hand, TRIUMF Innovations Inc. (“TI”), a not-for-profit corporation continued under the Canada Not-for-profit Corporations Act, with its registered offices at 4004 Wesbrook Mall, Vancouver BC V6T 2A3, Canada and TRIUMF JV, a joint venture of The Governors of The University of Alberta, The University of British Columbia, The Governors of the University of Calgary, Carleton University, University of Guelph, University of Manitoba, McMaster University, Université de Montréal, Queen’s University, University of Regina, Simon Fraser University, The G
ASTRAZENECA AB — and — 15863210 CANADA INC. — and — FUSION PHARMACEUTICALS INC. ARRANGEMENT AGREEMENT March 18, 2024Arrangement Agreement • March 19th, 2024 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
ASTRAZENECA AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden, having its official seat in Södertälje, Sweden, its registered office address at 151 85 Södertälje, Sweden and registered with the trade register of the Swedish Companies Registration Office under number 556011-7482 (the Parent)
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Loan and Security Agreement • November 8th, 2022 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of September 21, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314, as collateral agent (in its individual capacity, “Oxford”; and in its capacity as collateral agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time including Oxford in its capacity as a Lender, OXFORD FINANCE CREDIT FUND II, LP, by its manager Oxford Finance Advisors, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“OFCF II”) (each a “Lender” and collectively, the “Lenders”), FUSION PHARMACEUTICALS INC., a corporation organized under the federal laws of Canada (“CAN Borrower”), with an office located at 270 Longwood Road South, Hamilton, Ontario, L8P 0A6, Canada, and FUSION PHARMACEUTICALS US
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Master Service Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
This Master Service Agreement (the “Agreement”), effective as of February 22, 2017 (the “Effective Date”), is established between Centre for Probe Development and Commercialization, a not-for-profit research and services institution with offices located at McMaster University, Nuclear Research Building, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, (“CPDC”), and Fusion Pharmaceuticals Inc. (“FUSION”), having a place of business at Nuclear Research Building, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, to define the general conditions to govern any contracted services to be undertaken for FUSION by CPDC. In this Agreement, FUSION and CPDC may be referred to individually each as “Party” or collectively as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Loan and Security Agreement • November 8th, 2022 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
THIS CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of August 23, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314, as collateral agent (in its individual capacity, “Oxford”; and in its capacity as collateral agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), FUSION PHARMACEUTICALS INC., a corporation organized under the federal laws of Canada (“CAN Borrower”), with an office located at 270 Longwood Road South, Hamilton, Ontario, L8P 0A6, Canada, and FUSION PHARMACEUTICALS US INC., a Delaware corporation (“US Borrower” and together with CAN Borrower, individually and collectively as the context requires, jointly and severally, “Borrower”),
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Loan and Security Agreement • May 11th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of March 30, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314, as collateral agent (in its individual capacity, “Oxford”; and in its capacity as collateral agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time including Oxford in its capacity as a Lender, OXFORD FINANCE CREDIT FUND II, LP, by its manager Oxford Finance Advisors, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“OFCF II”), OXFORD FINANCE FUNDING IX, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“OFF IX”), OXFORD FINANCE FUNDING 2023-1, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“OFF 2023-1”), OXFORD FINANCE
TWO INTERNATIONAL PLACE Boston, Massachusetts OFFICE LEASE FUSION PHARMACEUTICALS US INC.Office Lease • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
Agreement dated October 1,2019, between Fort Hill Square 2 Owner LLC, a Delaware limited liability company (“Landlord”), and Fusion Pharmaceuticals US Inc., a Delaware corporation (“Tenant”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Strategic Collaboration Agreement • November 2nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This STRATEGIC COLLABORATION AGREEMENT (the “Agreement”) is entered into as of the [•] day of October, 2020 (the “Effective Date”) by and between FUSION PHARMACEUTICALS INC., a Canadian federal corporation with its registered offices at 270 Longwood Road S, Hamilton, Ontario L8P 0A6 (“Fusion”), and ASTRAZENECA UK LIMITED, a company incorporated in England and Wales (company number 03674842) whose registered address is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom CB2 0AA (“AstraZeneca”). AstraZeneca and Fusion each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in ARTICLE 1. All attached appendices, exhibits and schedules are a part of this Agreement.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • February 16th, 2024 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This License Agreement (“Agreement”), made as of 16 February 2024 (“Effective Date”), is by and among Fusion Pharmaceuticals Inc having an address at 270 Longwood Road South Hamilton, Ontario, Canada L8P 0A6 (“Fusion”) and Universität Heidelberg having an address at Grabengasse 1, 69117, Heidelberg, Germany (“UH”) and Euratom represented by the European Commission, Joint Research Centre (“EURATOM”), having an address at B-1049, Brussels, Belgium (“Euratom”). EURATOM, Fusion, and UH are each referred to individually as a “Party” and together as the “Parties.” UH and EURATOM, co-owner of the Licensed patents, are together referred to as “Licensors” or “Licensor” as applicable.
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 19th, 2024 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This Amendment (the “Amendment”) to that certain Employment Agreement, dated as of December 18, 2023 (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and Eric Burak (the “Executive”) and is effective as of March 18, 2024 (the “Effective Date”).
AMENDMENT No. 1 EMPLOYMENT AGREEMENTEmployment Agreement • March 25th, 2021 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (the “Amendment”) to that certain Employment Agreement, dated as of June 25, 2020 (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and John Valliant (the “Executive”) and is effective as of February 19, 2021 (the “Effective Date”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Supply Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This Supply Agreement is conducted under the general provisions of the Master Services Agreement and the Quality Agreement entered into between the PARTIES. Unless explicitly stated within this Supply Agreement should there be discrepancies between the Supply Agreement and the Master Services Agreement, then the Master Services Agreement will be the controlling document.
AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSMFusion Pharmaceuticals Inc. • January 19th, 2024 • Biological products, (no disgnostic substances)
This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment No. 1”) is entered into as of the date first written above by and between Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and Jefferies LLC, as sales agent and/or principal (the “Agent”), as parties to that certain Open Market Sale AgreementSM, dated July 2, 2021 (the “Sales Agreement”) relating to the offering of up to $100,000,000 of the Company’s common shares, no par value per share (the “Common Shares”).
